Tumor mutation burden (TMB) is considered an important predictive biomarker for the efficacy of immunotherapy. However, in cancer types where TMB is not positively correlated with the abundance of CD8 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results